DOCSLIB.ORG

Federal Register/Vol. 86, No. 100/Wednesday, May 26, 2021/Proposed Rules

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 86, No. 100/Wednesday, May 26, 2021/Proposed Rules Federal Register / Vol. 86, No. 100 / Wednesday, May 26, 2021 / Proposed Rules 28301 DEPARTMENT OF COMMERCE comments. Attachments to electronic expected to have a minimal impact on comments will be accepted in ADOBE® applicants in general. Patent and Trademark Office portable document format or The USPTO encourages applicants to MICROSOFT WORD® format. Because file their patent applications via its 37 CFR Part 1 comments will be made available for USPTO patent electronic filing system and imposes a surcharge for non- [Docket No. PTO–P–2020–0032] public inspection, information that the submitter does not desire to make electronic filing of an original patent RIN 0651–AD48 public, such as an address or phone application (excluding reissue, design, number, should not be included in the plant, and provisional applications), as Electronic Submission of a Sequence comments. mandated by section 10(h) of Public Listing, a Large Table, or a Computer Visit the Federal eRulemaking Portal Law 112–29, September 16, 2011 Program Listing Appendix in Patent (Leahy-Smith America Invents Act). The Applications website (www.regulations.gov) for additional instructions on providing USPTO provides information (Legal AGENCY: United States Patent and comments via the portal. If electronic Framework for Patent Electronic Trademark Office, Department of submission of comments is not feasible System) concerning electronic filing via Commerce. due to lack of access to a computer and/ the USPTO patent electronic filing system on its website at www.uspto.gov/ ACTION: Notice of proposed rulemaking. or the internet, please contact the USPTO using the contact information patents-application-process/filing- SUMMARY: The United States Patent and below for special instructions. online/legal-framework-efs-web and in Trademark Office (USPTO or Office) section 502.05 of the Manual of Patent proposes to amend the rules of practice FOR FURTHER INFORMATION CONTACT: Examining Procedure (MPEP, Ninth to permit higher-capacity physical Mary C. Till, Senior Legal Advisor, Edition, Revision 10.2019). In media to be submitted to the USPTO. Office of Patent Legal Administration, particular, the USPTO patent electronic Patent applications for certain Office of the Deputy Commissioner for filing system permits submission of inventions require significant data in Patents, by email at Mary.Till@ ASCII plain text files (.txt) for American Standard Code for uspto.gov; or Ali Salimi, Senior Legal submission of a ‘‘Sequence Listing,’’ a Information Interchange (ASCII) text Advisor, Office of Patent Legal CRF of a ‘‘Sequence Listing,’’ ‘‘Large format to be submitted to the USPTO in Administration, Office of the Deputy Tables,’’ and a ‘‘Computer Program order to determine whether the Commissioner for Patents, by email at Listing Appendix.’’ Although a USPTO invention described in the patent [email protected]. Contact via patent electronic filing system application is patentable. When telephone at 571–272–7704 if further submission of such ASCII plain text submission of such data exceeds the instruction is needed for the submission files is preferred, it is possible that the USPTO’s patent electronic filing system of comments. system limitations of the USPTO patent capacity, direct submission would not SUPPLEMENTARY INFORMATION: electronic filing system may not accommodate large ASCII text files. be possible for a large data submission Background: In order to permit the Currently, in those circumstances, such in ASCII text format. To that end, the submission of large amounts of data in text files may be submitted on compact rules of practice are proposed to be patent applications where such a disc under 37 CFR 1.52(e), and images amended to provide applicants with the submission exceeds the capacity for of such text files may be submitted in ability to use physical media larger than filing via the USPTO patent electronic Portable Document Format (PDF) via the compact discs (CDs) for submission of filing systems, this rulemaking seeks to USPTO patent electronic filing system an electronic version of amino acid and expand the types of physical media that (except for a CRF of a ‘‘Sequence nucleotide sequence information, can be used for such a submission. The Listing’’ or a ‘‘Computer Program Listing information compiled in a large table, volume of applications in which such and information relating to a computer Appendix’’ having over 300 lines—these large amounts of data may need to be must be submitted on compact disc program listing. Additionally, changes submitted is a small fraction of the total regarding extraction of compressed data under 37 CFR 1.52(e)). The proposed number of applications that the USPTO changes to the rules of practice files, which had not been permitted in receives every year. Expanding the types pertaining to a ‘‘Sequence Listing,’’ a the past for certain submissions, would of physical media that can be used by CRF of a ‘‘Sequence Listing,’’ ‘‘Large be permitted if compliant with the these applicants achieves the intent Tables,’’ and a ‘‘Computer Program requirements of the proposed rules. with minimal changes to the USPTO’s Listing Appendix’’ would harmonize Other rules relating to certain obsolete processing of such large amounts of the rules for filing such documents in and non-secure methods of presenting data. electronic form with the requirements data would be eliminated. With respect to the submission of data and conditions set forth in the Legal DATES: Comments must be received by relating to biotechnology inventions, the Framework for Patent Electronic July 26, 2021 to ensure consideration. proposed rules would no longer permit System. The proposed changes do not ADDRESSES: For reasons of Government an applicant to rely on a previously alter the requirements and conditions efficiency, comments must be submitted submitted computer readable form set forth in the Legal Framework for through the Federal eRulemaking Portal (CRF) of required sequence information. Patent Electronic System. at www.regulations.gov. To submit The proposed rules thus ensure the Submission of ASCII plain text files: comments via www.regulations.gov, robustness of the data by requiring the Currently, electronic documents in enter docket number PTO–P–2020–0032 applicant to confirm that the data ASCII file format that are to become part on the homepage and click ‘‘Search.’’ presented is the correct information for of the permanent USPTO records in the The site will provide a search results the examiner to consider during the file of a patent application, page listing all documents associated examination process. Since the reexamination, or supplemental with this docket. Find a reference to this proposed rules will also permit an examination proceeding that exceed the document and click on the ‘‘Comment ASCII plain text file to serve as both the USPTO patent electronic filing system Now!’’ icon, complete the required sequence listing itself and the CRF of limits may be submitted on a compact fields, and enter or attach your the sequence listing, these changes are disc. Due to the limited storage capacity VerDate Sep<11>2014 18:54 May 25, 2021 Jkt 253001 PO 00000 Frm 00004 Fmt 4702 Sfmt 4702 E:\FR\FM\26MYP1.SGM 26MYP1 28302 Federal Register / Vol. 86, No. 100 / Wednesday, May 26, 2021 / Proposed Rules of compact discs, the USPTO is ‘‘Computer Program Listing Appendix’’ included in the specification, in proposing revisions to permit use of (unless capable of being divided) and accordance with 37 CFR 1.76, it should Digital Video Disc-Recordable (DVD–R above 100 MB for a ‘‘Sequence Listing’’ be noted that the USPTO does not or DVD+R). These higher-capacity read- will have to be submitted on read-only recognize a benefit or priority claim only optical discs, on which data is optical discs. Submission of a presented only in the specification for permanently recorded and cannot be ‘‘Sequence Listing’’ as an ASCII text file, patent applications filed on or after changed or erased, significantly reduce if it exceeds 100 MB, cannot be divided September 16, 2012. For these the number of physical media required like a submission of a ‘‘Large Table’’ or applications or patents issued from such to accommodate large files. a ‘‘Computer Program Listing applications, a benefit claim (37 CFR In the case of a ‘‘Sequence Listing,’’ Appendix.’’ Thus, any ‘‘Sequence 1.78) or priority claim (37 CFR 1.55) MPEP section 2422.03 indicates that if Listing’’ greater than 100 MB must be must be presented on an Application a new application is filed via the submitted on read-only optical discs. Data Sheet for an original application in USPTO patent electronic filing system Currently, such files cannot be order to be recognized by the USPTO. with an ASCII plain text file of a compressed; this can necessitate the use Sequence Listings: Any patent ‘‘Sequence Listing’’ that complies with of multiple CD–ROMs or CD–Rs. These application that contains unbranched the requirements of 37 CFR 1.824(a)(2) proposed changes to the rules of nucleotide sequences with 10 or more through (6) and (b), and the applicant practice will permit higher-capacity nucleotide bases or unbranched, non-D has not filed a ‘‘Sequence Listing’’ in a media as well as non-self-extracting file amino acid sequences with 4 or more PDF image file, the text file will serve compression. By permitting file amino acids, provided that there are at as both the paper copy required by 37 compression, material submitted on a least 10 ‘‘specifically defined’’ CFR 1.821(c) and the CRF required by read-only optical disc will be capable of nucleotides or 4 ‘‘specifically defined’’ 37 CFR 1.821(e). This concept is fitting on a single disc with the data amino acids, must contain a ‘‘Sequence expressly incorporated into these integrity remaining intact. Listing’’ and a CRF of the ‘‘Sequence proposed changes to the rules of The current rules of practice (37 CFR Listing.’’ Under the current rules, a practice.
Load more

Recommended publications
  • Collagen and Elastin Fibres
    J Clin Pathol: first published as 10.1136/jcp.s3-12.1.49 on 1 January 1978. Downloaded from J. clin. Path., 31, Suppl. (Roy. Coll. Path.), 12, 49-58 Collagen and elastin fibres A. J. BAILEY From the Agricultural Research Council, Meat Research Institute, Langford, Bristol Although an understanding of the intracellular native collagen was generated from type I pro- biosynthesis of both collagen and elastin is of collagen. Whether this means that the two pro- considerable importance it is the subsequent extra- collagens are converted by different enzyme systems cellular changes involving fibrogenesis and cross- and the type III enzyme was deficient in these linking that ensure that these proteins ultimately fibroblast cultures, or that the processing of pro become the major supporting tissues of the body. type III is extremely slow, is not known. The latter This paper summarises the formation and stability proposal is consistent with the higher proportion of collagen and elastin fibres. of soluble pro type III extractable from tissue (Lenaers and Lapiere, 1975; Timpl et al., 1975). Collagen Basement membrane collagens, on the other hand, do not form fibres and this property may be The non-helical regions at the ends of the triple due to the retention of the non-helical extension helix of procollagen probably provide a number of peptides (Kefalides, 1973). In-vivo biosynthetic different intracellular functions-that is, initiating studies showing the absence of any extension peptide rapid formation of the triple helix; inhibiting intra- removal support this (Minor et al., 1976), but other cellular fibrillogenesis; and facilitating transmem- workers have reported that there is some cleavage brane movement.
    [Show full text]
  • 01. Amino Acids
    01. Amino Acids 1 Biomolecules • Protein • Carbohydrate • Nucleic acid • Lipid 2 peptide polypeptide protein di-, tri-, oligo- 3 4 fibrous proteins proteins globular proteins 5 Figure 4.1 Anatomy of an amino acid. Except for proline and its derivatives, all of the amino acids commonly found in proteins possess this type of structure. 6 Glycine (Gly, G) Alanine (Ala, A) Valine (Val, V)* Leucine (Leu, L)* Isoleucine (Ile. I)* 7 Serine (Ser, S) Threonine (Thr, T)* Cysteine (Cys, C)cystine Methionine (Met, M)* 8 Aspartate (Asp, D) Glutamate (Glu, E) Asparagine (Asn, N) Glutamine (Gln, Q) 9 Lysine (Lys, K)* Arginine (Arg, R)* 10 Phenylalanine (Phe, F)* Tyrosine (Tyr, Y) Histidine (His, H)* Tryptophan (Trp, W)* 11 Proline (Pro, P) 12 Hydrophobic (A, G, I, L, F, V, P) Hydrophilic (D, E, R, S, T, C, N, Q, H) Amphipathic (K, M, W, Y) 13 Essential amino acids: V, L, I, T, M, K, R, F, H, W 14 Several Amino Acids Occur Rarely in Proteins We'll see some of these in later chapters • Selenocysteine in many organisms • Pyrrolysine in several archaeal species • Hydroxylysine, hydroxyproline - collagen • Carboxyglutamate - blood-clotting proteins • Pyroglutamate – in bacteriorhodopsin • GABA, epinephrine, histamine, serotonin act as neurotransmitters and hormones • Phosphorylated amino acids – a signaling device Several Amino Acids Occur Rarely in Proteins Several Amino Acids Occur Rarely in Proteins Figure 4.4 (b) Some amino acids are less common, but nevertheless found in certain proteins. Hydroxylysine and hydroxyproline are found in connective-tissue proteins; carboxy- glutamate is found in blood-clotting proteins; pyroglutamate is found in bacteriorhodopsin (see Chapter 9).
    [Show full text]
  • Subject Index
    Cambridge University Press 0521462924 - Amino Acids and Peptides G. C. Barrett and D. T. Elmore Index More information Subject index acetamidomalonate synthesis 123–4 in fossil dating 15 S-adenosyl--methionine 11, 12, 174, 181 in geological samples 15 alanine, N-acetyl 9 in Nature 1 structure 4 IR spectrometry 36 alkaloids, biosynthesis from amino acids 16–17 isolation from proteins 121 alloisoleucine 6 mass spectra 61 allosteric change 178 metabolism, products of 187 allothreonine 6 metal-binding properties 34 Alzheimer’s disease 14 NMR 41 amidation at peptide C-terminus 57, 94, 181 physicochemical properties 32 amides, cis–trans isomerism 20 protein 3 N-acylation 72 PTC derivatives 87 N-alkylation 72 quaternary ammonium salts 50 hydrolysis 57 reactions of amino group 49, 51 O-trimethylsilylation 72 reactions of carboxy group 49, 53 reduction to ␤-aminoalkanols 72 racemisation 56 amidocarbonylation in amino acid synthesis 125 routine spectrometry 35 amino acids, abbreviated names 7 Schöllkopf synthesis 127–8 acid–base properties 32 Schiff base formation 49 antimetabolites 200 sequence determination 97 et seq. as food additives 14 following selective chemical degradation 107 as neurotransmitters 17 following selective enzymic degradation 109 asymmetric synthesis 127 general strategy for 92 ␤- 17–18 identification of C-terminus 106–7 biosynthesis 121 identification of N-terminus 94, 97 biosynthesis from, of creatinine 183 by solid-phase methodology 100 of nitric oxide 186 by stepwise chemical degradation 97 of porphyrins 185 by use of dipeptidyl
    [Show full text]
  • A Few Experimental Suggestions Using Minerals to Obtain Peptides with a High Concentration of L-Amino Acids and Protein Amino Acids
    S S symmetry Hypothesis A Few Experimental Suggestions Using Minerals to Obtain Peptides with a High Concentration of L-Amino Acids and Protein Amino Acids Dimas A. M. Zaia 1,* and Cássia Thaïs B. V. Zaia 2 1 Laboratório de Química Prebiótica-LQP, Departamento de Química, Universidade Estadual de Londrina, CEP 86 057-970 Londrina, Brazil 2 Laboratório de Fisiologia Neuroendocrina e Metabolismo–LaFiNeM, Departamento de Ciências Fisiológicas, Universidade Estadual de Londrina, CEP 86 057-970 Londrina, Brazil; [email protected] * Correspondence: [email protected] Received: 9 October 2020; Accepted: 25 November 2020; Published: 10 December 2020 Abstract: The peptides/proteins of all living beings on our planet are mostly made up of 19 L-amino acids and glycine, an achiral amino acid. Arising from endogenous and exogenous sources, the seas of the prebiotic Earth could have contained a huge diversity of biomolecules (including amino acids), and precursors of biomolecules. Thus, how were these amino acids selected from the huge number of available amino acids and other molecules? What were the peptides of prebiotic Earth made up of? How were these peptides synthesized? Minerals have been considered for this task, since they can preconcentrate amino acids from dilute solutions, catalyze their polymerization, and even make the chiral selection of them. However, until now, this problem has only been studied in compartmentalized experiments. There are separate experiments showing that minerals preconcentrate amino acids by adsorption or catalyze their polymerization, or separate L-amino acids from D-amino acids. Based on the [GADV]-protein world hypothesis, as well as the relative abundance of amino acids on prebiotic Earth obtained by Zaia, several experiments are suggested.
    [Show full text]
  • Collagen Structural Microheterogeneity and a Possible Role for Glycosylated Hydroxylysine in Type 1 Collagen
    Proc. NatL Acad. Sci. USA Vol. 79, pp. 7684-7688, December 1982 Biochemistry Collagen structural microheterogeneity and a possible role for glycosylated hydroxylysine in type 1 collagen (nonreducible stable crosslinks/hydroxyaldolhistidine/specific cleavage/molecular location) MITSUO YAMAUCHI*t, CLAUDIA NOYES*t, YOSHINORI KUBOKI*t, AND GERALD L. MECHANIC*§¶ *Dental Research Center, §Department of Biochemistry and Nutrition, and tDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina 27514 Communicated by. Ernest L. Eliel, September 20, 1982 ABSTRACT A three-chained peptide from type I collagen, and Mechanic (8) that dehydro-HisOHMerDes, which was crosslinked by hydroxyaldolhistidine, has been isolated from a thought to be artifactual (9, 10) is a true crosslink in collagen tryptic digest of5 M guanidine HCI-insoluble bovine skin collagen fibrils. Bernstein and Mechanic found that one HisOHMerDes (a small but as yet unknown percentage of the total collagen in crosslink was present per molecule of collagen in freshly re- whole skin). Os04/NaIO4 specifically cleaved the crosslink at its constituted soluble collagen fibrils. double bond into a two-chained crosslink peptide and a single pep- Histidine was also found to be a constituent of the stable tide. The sequence of the two-chained peptide containing the bi- nonreducible trifunctional crosslink hydroxyaldolhistidine functional crosslink was determined after amino acid analysis of (OHAlHis), whose structure was elucidated by PMR and mass the separated peptides. The crosslink consists of an aldehyde de- spectrometry rived from hydroxylysine-87 in the aldehyde-containing cyanogen (11). OHAIHis was isolated from bovine skin col- bromide fragment alCB5ald and an aldehyde derived from the lagen.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,874,589 Campbell Et Al
    USOO5874589A United States Patent (19) 11 Patent Number: 5,874,589 Campbell et al. 45) Date of Patent: Feb. 23, 1999 54 METHODS FOR SYNTHESIZING DIVERSE El Marini et al., 1992, Synthesis pp. 1104-1108 Synthesis of COLLECTIONS OF TETRAMIC ACIDS AND enantiomerically pure B-and Y-amino acids from aspartic DERVATIVES THEREOF and glutamic acid derivatives. Evans et al., 1982, J. Amer. Chem. Soc. 104: 1737–1739 75 Inventors: David A. Campbell, San Mateo; Todd Asymmetric alkylation reactions of chiral imide enolates. A T. Romoff, San Jose, both of Calif. practical approach to the enantioselective Synthesis of C-Substituted carboxylic acid derivatives. 73 Assignee: GlaxoWellcome, Inc., Research Fontenot et al., 1991, Peptide Research, 4: 19-25A Survey Triangle Park, N.C. of potential problems and qulaity control in peptide Synthe sis by the flourenylmethocvarbonyl procedure. 21 Appl. No.: 896,799 Giesemann et al., 1982, J. Chem. Res. (S) pp. 79 Synthesis 22 Filed: Jul.18, 1997 of chiral C-isocyano esters and other base-Sensitive isocya nides with 51) Int. Cl. ........................ C07D 211/40; CO7D 207/00 oxomethylenebis-(3H-Imidazolium)Bis(methanesulphonate), 52 U.S. Cl. ............ ... 548/540; 546/220; 548/539 a versatile dehydrating reagent. 58 Field of Search ............................. 546/220; 548/539, Geysen et al., 1987, J. Immunol. Meth. 102: 259-274 548/540 Strategies for epitope analysis using peptide Synthesis. Giron-Forest et al., 1979, Analytical Profiles of Drug Sub 56) References Cited stances, 8: 47-81 Bromocriptine methaneSulphonate. U.S. PATENT DOCUMENTS Gokeletal, 1971, Isonitrile Chemistry, Ugi, I. ed., Academic 3,299.095 1/1967 Harris et al.
    [Show full text]
  • SUPPLEMENTARY TABLE 1 Non-Destructive Characterisation Of
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2016 SUPPLEMENTARY TABLE 1 Non-destructive characterisation of mesenchymal stem cell differentiation using LC-MS-based metabolite footprinting Amal Surrati 1, Rob Linforth 2, Ian Fisk 2, VirginieSottile1*, Dong-Hyun Kim 3*. 1Wolfson Centre for Stem Cells, Tissue, Engineering and Modelling (STEM), School of Medicine, The University of Nottingham, CBS Building - University Park, Nottingham NG7 2RD (U.K.) 2Division of Food Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD (U.K.) 3Centre for Analytical Bioscience, Division of Molecular and Cellular Sciences, School of Pharmacy, The University of Nottingham, Nottingham, NG7 2RD (U.K.) *Correspondence to: Email: [email protected] Tel: +44 1158231235 Email: [email protected] Tel: +44 1157484697 Supplementary Table 1: Metabolites changed in MSC-conditioned medium compared to fresh medium (blank). ↑ indicates the metabolites that increased in all MSC-conditioned medium (control and OS) compared to their corresponding blanks, and ↓ indicates decreased metabolites. ID confidence: Metabolite identification level according to the metabolomics standards initiative 29,30 ; L1 – Level 1, L2 – Level 2. Change RT ID Identifier compared Exact mass Formula Putative metabolite (min) confidence (PubChem) to blank medium 179.0946 5.30 C10H13NO2 (-)-Salsolinol L2 91588 ↑ 358.1410 10.12 C20H22O6 (+)-Pinoresinol L2 7741 ↑ 148.0371
    [Show full text]
  • Synthetic Polynucleotides Synthetische Polynukleotide Polynucleotides Synthetiques
    Europäisches Patentamt *EP000960192B1* (19) European Patent Office Office européen des brevets (11) EP 0 960 192 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C12N 9/02, C12N 15/53, of the grant of the patent: A61K 38/43, C12N 9/06 09.11.2005 Bulletin 2005/45 (86) International application number: (21) Application number: 97933592.4 PCT/AU1997/000505 (22) Date of filing: 11.08.1997 (87) International publication number: WO 1998/006830 (19.02.1998 Gazette 1998/07) (54) SYNTHETIC POLYNUCLEOTIDES SYNTHETISCHE POLYNUKLEOTIDE POLYNUCLEOTIDES SYNTHETIQUES (84) Designated Contracting States: • SHARP P M ET AL: "The codon Adaptation AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC Index--a measure of directional synonymous NL PT SE codon usage bias, and its potential applications." NUCLEIC ACIDS RESEARCH. (30) Priority: 09.08.1996 AU PO156596 ENGLAND 11 FEB 1987, vol. 15, no. 3, 11 February 1987 (1987-02-11), pages 1281-1295, (43) Date of publication of application: XP001122356 ISSN: 0305-1048 01.12.1999 Bulletin 1999/48 • DATABASE SWISSPROT [Online] 1 December 1992 (1992-12-01) MARIANI T.J. ET AL.: (60) Divisional application: "Protein-lysine 6-oxidase precursor (EC 05000327.6 1.4.3.13) (Lysyl oxidase)." Database accession no. P28300 XP002229125 (73) Proprietor: THE UNIVERSITY OF SYDNEY • DATABASE EMBL [Online] EBI; 16 May 1992 Sydney, New South Wales 2006 (AU) (1992-05-16) MARIANI T.J. ET AL.: "Human lysyl oxidase (LOX) mRNA, complete cds." Database (72) Inventor: WEISS, Anthony, Steven accession no. M94054 XP002229126 Randwick, NSW 2031 (AU) • DATABASE EMBL [Online] EBI; 26 November 1993 (1993-11-26) HAMALAINEN E.R.
    [Show full text]
  • Preferential Import of Queuosine-Modified Trnas Into
    Published online 9 July 2021 Nucleic Acids Research, 2021, Vol. 49, No. 14 8247–8260 https://doi.org/10.1093/nar/gkab567 Preferential import of queuosine-modified tRNAs into Trypanosoma brucei mitochondrion is critical for organellar protein synthesis Sneha Kulkarni1,2, Mary Anne T. Rubio1,3,EvaHegedusov˝ a´ 1, Robert L. Ross4, Patrick A. Limbach 5, Juan D. Alfonzo3 and Zdenekˇ Paris 1,2,* 1Institute of Parasitology, Biology Centre, Czech Academy of Sciences, Ceskˇ eBud´ ejovice,ˇ Czech Republic, 2Faculty 3 of Science, University of South Bohemia, Ceskˇ eBud´ ejovice,ˇ Czech Republic, Department of Microbiology and The Downloaded from https://academic.oup.com/nar/article/49/14/8247/6318497 by guest on 01 October 2021 Center for RNA Biology, The Ohio State University, Columbus, OH, USA, 4Metabolomics Mass Spectrometry Core, Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA and 5Rieveschl Laboratories for Mass Spectrometry, Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA Received November 30, 2020; Revised May 28, 2021; Editorial Decision June 13, 2021; Accepted June 21, 2021 ABSTRACT sine (Q), a hypermodified 7-deaza-guanosine, is one of the most chemically intricate modifications described to date. Transfer RNAs (tRNAs) are key players in protein syn- Q is found at the wobble position 34 of tRNAs that contain thesis. To be fully active, tRNAs undergo extensive a5-GUN-3 anticodon sequence, where N represents any post-transcriptional modifications, including queuo- of the canonical nucleotides, which includes tRNAHisGUG, sine (Q), a hypermodified 7-deaza-guanosine present tRNAAspGUC, tRNAAsnGUU, tRNATyr GUA (3). Q is in the anticodon of several tRNAs in bacteria and eu- found in both bacteria and eukarya, and catalyzed by tRNA karya.
    [Show full text]
  • Discovery of Novel Bacterial Queuine Salvage Enzymes and Pathways in Human Pathogens
    Discovery of novel bacterial queuine salvage enzymes and pathways in human pathogens a,1 b,1 c,1 b d a Yifeng Yuan , Rémi Zallot , Tyler L. Grove , Daniel J. Payan , Isabelle Martin-Verstraete , Sara Sepic´ , Seetharamsingh Balamkundue, Ramesh Neelakandane, Vinod K. Gadie, Chuan-Fa Liue, Manal A. Swairjof,g, Peter C. Dedone,h,i, Steven C. Almoc, John A. Gerltb,j,k, and Valérie de Crécy-Lagarda,l,2 aDepartment of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611; bInstitute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, IL 61801; cDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461; dLaboratoire de Pathogénèse des Bactéries Anaérobies, Institut Pasteur et Université de Paris, F-75015 Paris, France; eSingapore-MIT Alliance for Research and Technology, Infectious Disease Interdisciplinary Research Group, 138602 Singapore, Singapore; fDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, CA 92182; gThe Viral Information Institute, San Diego State University, San Diego, CA 92182; hDepartment of Biological Engineering and Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139; iCenter for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; jDepartment of Biochemistry, University of Illinois at Urbana–Champaign, Urbana, IL 61801; kDepartment of Chemistry, University of Illinois at Urbana–Champaign, Urbana, IL 61801; and lUniversity of Florida Genetics Institute, Gainesville, FL 32610 Edited by Tina M. Henkin, The Ohio State University, Columbus, OH, and approved August 1, 2019 (received for review June 16, 2019) Queuosine (Q) is a complex tRNA modification widespread in 1A. The TGT enzyme, which is responsible for the base ex- eukaryotes and bacteria that contributes to the efficiency and accuracy change, is the signature enzyme in the Q biosynthesis pathway.
    [Show full text]
  • Unveiling Structural and Functional Divergences Of
    Unveiling structural and functional divergences of bacterial tRNA dihydrouridine synthases: perspectives on the evolution scenario Charles Bou-Nader, Hugo Montémont, Vincent Guérineau, Olivier Jean-Jean, Damien Brégeon, Djemel Hamdane To cite this version: Charles Bou-Nader, Hugo Montémont, Vincent Guérineau, Olivier Jean-Jean, Damien Brégeon, et al.. Unveiling structural and functional divergences of bacterial tRNA dihydrouridine synthases: per- spectives on the evolution scenario. Nucleic Acids Research, Oxford University Press, 2018, 46 (3), pp.1386-1394. 10.1093/nar/gkx1294. hal-01727508 HAL Id: hal-01727508 https://hal.sorbonne-universite.fr/hal-01727508 Submitted on 9 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License 1386–1394 Nucleic Acids Research, 2018, Vol. 46, No. 3 Published online 27 December 2017 doi: 10.1093/nar/gkx1294 Unveiling structural and functional divergences of bacterial tRNA dihydrouridine synthases: perspectives on the evolution scenario Charles
    [Show full text]
  • Ratio of Phosphate to Amino Acids
    National Institute for Health and Care Excellence Final Neonatal parenteral nutrition [D10] Ratio of phosphate to amino acids NICE guideline NG154 Evidence reviews February 2020 Final These evidence reviews were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]